Wenxin Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenxin Dong has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Boyuan Mei
School of Basic Medical Sciences, Institute for Immunology, Tsinghua University 2 State Key Laboratory of Molecular Oncology Beijing
1 shared publication - Chengyang Liu
School of Basic Medical Sciences, Institute for Immunology, Tsinghua University 2 State Key Laboratory of Molecular Oncology Beijing
1 shared publication - Dali Han
China National Center for Bioinformation, Beijing Institute of Genomics, Chinese Academy of Sciences 3 Department of Computational Biology, Key Laboratory of RNA Science and Engineering Beijing
1 shared publication - Feng Lin
College of Chemistry and Molecular Engineering, Peking University 1 New Cornerstone Science Laboratory, Synthetic and Functional Biomolecules Center, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, Beijing National Laboratory for Molecular Sciences Beijing
1 shared publication - Guanghao Liang
China National Center for Bioinformation, Beijing Institute of Genomics, Chinese Academy of Sciences 3 Department of Computational Biology, Key Laboratory of RNA Science and Engineering Beijing
1 shared publication - Jun Wang
Department of Pathology, New York University Grossman School of Medicine, New York, USA
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (6)
PRECISE-seq reveals disease-relevant TCR repertoires with phenotypic plasticity
Linking T cell phenotypes with antigen specificity and functional avidity is critical for understanding in vivo immune responses in infection and cancer. Here, we develop PRECISE-seq, a method that integrates multi-omics T cell analysis with contact-dependent proximity labeling for rapid screening of disease-relevant T cell repertoires, and for linking the relative TCR avidity with T cell phenotypes at single-cell resolution. PRECISE-seq accurately retrieves CMV-specific clonotypes from human peripheral blood and quantitatively measures functional avidity in physiological contexts. We find that high-potency CMV-specific T cells preferentially acquire an exhausted phenotype. In tumors, polyclonal tumor-reactive CD8+ T cells predominantly differentiate into a protumor Ly49+ regulatory state (TLy49), characterized by inhibitory killer cell lectin-like receptor expression and originating from effector memory T cells along a trajectory distinct from exhaustion. Notably, PD-1 blockade reduces TLy49 formation and promotes effector revival, which correlates with responsiveness to immunotherapy. Together, PRECISE-seq enables high-resolution mapping of TCR potency and T cell phenotype, revealing a regulatory axis shaping T cell fate in tumors.
- 12 May 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (6)
Open AccessPRECISE-seq reveals disease-relevant TCR repertoires with phenotypic plasticity
Linking T cell phenotypes with antigen specificity and functional avidity is critical for understanding in vivo immune responses in infection and cancer. Here, we develop PRECISE-seq, a method that integrates multi-omics T cell analysis with contact-dependent proximity labeling for rapid screening of disease-relevant T cell repertoires, and for linking the relative TCR avidity with T cell phenotypes at single-cell resolution. PRECISE-seq accurately retrieves CMV-specific clonotypes from human peripheral blood and quantitatively measures functional avidity in physiological contexts. We find that high-potency CMV-specific T cells preferentially acquire an exhausted phenotype. In tumors, polyclonal tumor-reactive CD8+ T cells predominantly differentiate into a protumor Ly49+ regulatory state (TLy49), characterized by inhibitory killer cell lectin-like receptor expression and originating from effector memory T cells along a trajectory distinct from exhaustion. Notably, PD-1 blockade reduces TLy49 formation and promotes effector revival, which correlates with responsiveness to immunotherapy. Together, PRECISE-seq enables high-resolution mapping of TCR potency and T cell phenotype, revealing a regulatory axis shaping T cell fate in tumors.